Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma

Genmab Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Seagen

Media Release COPENHAGEN, Denmark, and BOTHELL, Wash., February 24, 2022

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

BOTHELL, Wash., & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated a

Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2021 Results - Earning Calls Transcript

Genmab Publishes 2021 Annual Report

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021

Genmab and Synaffix Enter into License Agreement for ADC Technology

Media Release COPENHAGEN , Denmark; January 3 , 20 2 2 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 40 th  Annual J.P. Morgan Healthcare Conference at 9 :00 AM EST / 3 .00 PM CET on January 1 2 , 202 2 .  The live and archived webcast of the presentation will be available on Genmab's website at  https://ir.genmab.com/events-and-presentations#content .

Genmab to Present at the 40th Annual J.P. Morgan Healthcare Conference

Genmab has an impressive pipeline of proprietary and partnered programs in development. In addition, the company has developed or helped develop five FDA-approved monoclonal antibody therapies. The company's revenue is mostly recurring royalties and milestones through licensing of their novel and innovative technology. This business model creates steady revenue and long-term earnings growth.

Genmab: Ready For More Growth In 2022

Media Release Copenhagen, Denmark, December 13, 2021

Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base

Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2021 Results - Earnings Call Transcript

November 10, 2021; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2021

Genmab Announces Financial Results for the First Nine Months of 2021

Genmab Improves its 2021 Financial Guidance

AbbVie

Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)

Media Release Copenhagen, Denmark, November 0 3 , 20 2 1 Genmab A/S ( Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will take part in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2021. A webcast of the event will be available on Genmab's website from November 18, 2021, 9:00 AM CET at https://ir.genmab.com/events-and-presentations#content.

Genmab to Present at Jefferies Virtual London Healthcare Conference

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021

Incyte

Takeda Pharmaceutical

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NMEs, were approved in September.

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)

The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S' (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy.

FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer

COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is approved under the FDA's Accelerated Approval Progra

Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. TIVDAK is approved under the FDA's Accelerated Approval Progra

Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV) in recurrent or metastatic cervical cancer.

Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer

Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

NORTH CHICAGO, Ill., and COPENHAGEN, Denmark, Sept, 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part of the Phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL).

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet

News for Genmab - ADR Stock (GMAB)